Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 6/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 6/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ESRRA | P11474 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30294713 | 0.88 | TAS2R14 (0.52) | TAS2R14DHODHMPO | |
| SCHEMBL22853391 | 0.88 | TAS2R14 (0.52) | TAS2R14DHODHMPO | |
| SCHEMBL22853387 | 0.84 | CFTR (0.48) | CFTRTAS2R14SCN8ASCN10AMRGPRX4 | |
| SCHEMBL29383454 | 0.84 | CFTR (0.50) | CFTRTAS2R14SCN8ASCN10AMRGPRX4 | |
| SCHEMBL22833864 | 0.84 | CFTR (0.50) | CFTRTAS2R14SCN8ASCN10AMRGPRX4 | |
| SCHEMBL30294444 | 0.81 | TAS2R14 (0.50) | CFTRTAS2R14MRGPRX4DHODHMPO | |
| SCHEMBL22852770 | 0.81 | TAS2R14 (0.50) | CFTRTAS2R14MRGPRX4DHODHMPO | |
| SCHEMBL30294869 | 0.80 | SORT1 (0.46) | SCN8ASCN10ADHODHKDM4EHPGD | |
| SCHEMBL22853070 | 0.80 | SORT1 (0.46) | SCN8ASCN10ADHODHKDM4EHPGD | |
| SCHEMBL22853086 | 0.79 | CFTR (0.50) | CFTRTAS2R14SCN8ASCN10AMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
| WO-2020261114-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN1A, SCN1B | CFTR 402/4885TAS2R14 1406/4885SCN8A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.